Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
University of Utah
Taipei Medical University Shuang Ho Hospital
Wright State University
Case Comprehensive Cancer Center
OHSU Knight Cancer Institute
Roswell Park Cancer Institute
University of Nebraska
Case Comprehensive Cancer Center
University of California, Irvine
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
University of Chicago
Stanford University
University of Washington
OHSU Knight Cancer Institute
Vanderbilt-Ingram Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Northwestern University
Indiana University
M.D. Anderson Cancer Center
New Mexico Cancer Research Alliance
HaEmek Medical Center, Israel
HaEmek Medical Center, Israel
HaEmek Medical Center, Israel
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Health Research Institutes, Taiwan
University of Southern California
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center
Boston University
UNC Lineberger Comprehensive Cancer Center
Montefiore Medical Center
Rutgers, The State University of New Jersey
University of Pittsburgh